Table 2.
Compounds | Structure | S. aureus (ATCC 29213) | E. coli (ATCC 25922) | HC50 (μg/mL) | Selectivity (HC50/MIC) | EC50 (μg/mL) | |||
---|---|---|---|---|---|---|---|---|---|
MIC (μg/mL) | MLC (μg/mL) | MIC (μg/mL) | MLC (μg/mL) | S. aureus | E. coli | ||||
TMC (15i) | 8 | 64 | 256 | 256 | 6114 | 764 | 47.7 | 40 | |
TMC (15ii) | 32 | 32 | 64 | 64 | 6114 | 191 | 95.5 | - | |
TMC (15iii) | 4 | 4 | 64 | 64 | 6114 | 1528 | 95.5 | - | |
TMC (15iv) | 8 | 8 | 256 | 256 | 3072 | 764 | 47.7 | 10 | |
TMC (15v) | 32 | 32 | 256 | 1024 | 640 | 191 | - | - | |
TMA-CS (6i) | 8 | 8 | 16,384 | ≥32,768 | ≥32,768 | ≥4096 | ≥2 | 26 | |
TMA-CS (6ii) | 8 | 8 | 16,384 | 16,384 | ≥32,768 | ≥4096 | ≥2 | - | |
TMA-CS (6iii) | 32 | 32 | 16,384 | 16,384 | ≥32,768 | ≥1024 | ≥2 | - | |
TMA-CS (6iv) | 32 | 32 | ≥32,768 | ≥32,768 | ≥32,768 | ≥1024 | - | 66 | |
TMA-CS (6v) | 128 | 128 | ≥32,768 | ≥32,768 | ≥32,768 | ≥256 | - | - | |
PyA-CS (8i) | 8 | 1024 | 16,384 | 16,384 | ≥32,768 | ≥8192 | ≥2 | 38 | |
PyA-CS (8ii) | 8 | 512 | 8192 | 8192 | ≥32,768 | ≥8192 | ≥4 | - | |
PyA-CS (8iii) | 1024 | 1024 | 16,384 | 16,384 | ≥32,768 | ≥8 | ≥2 | - | |
PyA-CS (8iv) | 512 | 1024 | 16,384 | 16,384 | ≥32,768 | ≥16 | ≥2 | 12 | |
PyA-CS (8v) | 512 | 512 | 128 | 8192 | ≥32,768 | ≥64 | ≥256 | - | |
TMHA-CS (11i) | 1024 | 2048 | 256 | ≥32,768 | ≥32,768 | ≥32 | ≥128 | 644 | |
TMHA-CS (11ii) | 2048 | 2048 | 512 | 16,384 | ≥32,768 | ≥16 | ≥64 | - | |
TMHA-CS (11iii) | 1024 | 2048 | 128 | ≥32,768 | ≥32,768 | ≥4 | ≥256 | - | |
TMHA-CS (11iv) | 2048 | 4096 | 512 | ≥32,768 | ≥32,768 | ≥8 | ≥64 | 108 | |
TMHA-CS (11v) | 1024 | 4096 | 1024 | ≥32,768 | ≥32,768 | ≥32 | ≥32 | - | |
PyHA-CS (13i) | 4096 | 4096 | ≥32,768 | ≥32,768 | ≥32,768 | ≥8 | - | 4 | |
PyHA-CS (13ii) | 2048 | 2048 | ≥32,768 | ≥32,768 | ≥32,768 | ≥32 | - | - | |
PyHA-CS (13iii) | 8192 | 8192 | ≥32,768 | ≥32,768 | ≥32,768 | ≥4 | - | - | |
PyHA-CS (13iv) | 2048 | 2048 | 16,384 | 16,384 | ≥32,768 | ≥16 | ≥2 | 18 | |
PyHA-CS (13v) | 2048 | 2048 | ≥32,768 | ≥32,768 | ≥32,768 | ≥16 | - | - |
The antibacterial tests was done according the Clinical and Laboratory Standards Institute (CLSI) protocol (see Section 3.4.1). According to this procedure, a single dilution series was done for each compound, and gentamycin was used as a positive control. A difference of 1–2 dilutions is therefore not considered significant. The hemolysis measurements were also done in singlets for each concentration. The cytotoxicity measurements were carried out in triplicate, and the standard deviation varied from 10% to 22%.